PetMeds Q2 net sales fall 19.4% to $35.8M; net loss narrows to $6.4M ($0.31/sh)

PETMED EXPRESS INC

Net sales of $35.8M vs $44.4M a year ago, down 19.4%, driven by lower prescription medication sales and higher consumer promotional usage.
Net loss of $6.4M, or $(0.31) per diluted share, versus a net loss of $8.5M, or $(0.41) per diluted share, in the prior-year quarter.
Adjusted EBITDA was $(3.6)M, worse than $(2.3)M a year ago; lower G&A and advertising spend was offset by weaker gross profit and lower manufacturer rebates.
CEO Jeff Willard said operations are "stabilized"; customer acquisition cost fell 32% YoY, with focus on repositioning the brand and improving retention.
No financial guidance was provided in the release; earnings webcast scheduled for 4:30pm Eastern on November 10, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.